1. In Vivo

The J&J Lesson

 
• By Ken West, Jim Woodward, and Reinhard Merz

J&J's exit from the coronary angioplasty market was a sign of the end of an era. Without a product at the high end of innovation, it was left with a basic product that in the interim had become commoditized.

The first challenge to Johnson & Johnson’s coronary angioplasty business came from Guidant Corp.’s introduction of a stent with greater flexibility and an improved delivery balloon catheter. The results were stunning: Guidant captured a 70% market share within 45 days of launch and by the end of 1996, the J&J market share had dropped from 91% to 8%.

Market consolidation was moving at a rapid pace. Boston Scientific Corp. had bought SciMed Life Systems Inc. in late 1994 and Heart Technology Inc. soon thereafter.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on In Vivo for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Archive

More from In Vivo

The 360 Degrees Of European Biotech Financing In 2025

 
• By Jo Shorthouse

Almost halfway through 2025, and financing for European biotech could be described as challenging. Market volatility, geopolitical instability and trade barriers all loom large in biotech CEO minds when pitching for funding. In Vivo talked to biotechs and investors to gain a realistic view of the current market for company funding so far this year.

Rising Leaders 2025: Pedro Valencia’s ADC Vision At AbbVie

 
• By Jo Shorthouse

From chemical engineering to cancer innovation, AbbVie's rising oncology leader is advancing next-generation ADCs to tackle difficult-to-treat tumors with a patient-centered approach.

Leaders At The Frontier: Conversations From SynBioBeta 2025

 
• By David Wild

Mini-profiles of five synthetic biology companies and their leaders from SynBioBeta 2025 reveal how AI integration, data-driven platforms and interdisciplinary teams are revolutionizing drug discovery and manufacturing.